Gelfand Eli V, Cannon Christopher P
Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
J Am Coll Cardiol. 2006 May 16;47(10):1919-26. doi: 10.1016/j.jacc.2005.12.067. Epub 2006 Apr 24.
Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for the treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking. In four large trials, after one year of treatment, rimonabant 20 mg led to greater weight loss and reduction in waist circumference compared with placebo. Therapy with rimonabant is also associated with favorable changes in serum lipid levels and an improvement in glycemic control in prediabetes patients and in type 2 diabetic patients. At the same dose, rimonabant significantly increased cigarette smoking quit rates as compared with placebo. Rimonabant seems to be well tolerated, with a primary side effect of mild nausea. As an agent with a novel mechanism of action, rimonabant has a potential to be a useful adjunct to lifestyle and behavior modification in treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking.
利莫那班是一种新型的大麻素1型受体（CB1）选择性阻滞剂，正被开发用于治疗多种心血管代谢风险因素，包括腹型肥胖和吸烟。在四项大型试验中，经过一年的治疗，与安慰剂相比，20毫克利莫那班导致更多的体重减轻和腰围减小。利莫那班治疗还与血清脂质水平的有利变化以及糖尿病前期患者和2型糖尿病患者血糖控制的改善有关。在相同剂量下，与安慰剂相比，利莫那班显著提高了戒烟率。利莫那班似乎耐受性良好，主要副作用为轻度恶心。作为一种具有新型作用机制的药物，利莫那班有可能成为治疗多种心血管代谢风险因素（包括腹型肥胖和吸烟）的生活方式和行为改变的有用辅助药物。
